Erika Kelton devoted almost a decade to a whistleblower action against GlaxoSmithKline PLC, but it finally paid off to the tune of $3 billion. Kelton, a partner at Phillips & Cohen in Washington, was lead attorney for the firm in an off-label marketing case involving a number of prescription drugs, including asthma drug Advair. It was the largest health care fraud settlement to date, according to the U.S. Department of Justice.
Advair received U.S. Food and Drug Administration approval to treat serious forms of asthma, but Glaxo allegedly marketed it to patients suffering from milder forms of asthma, for which it has not been approved.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
